source
- Will the first approved psychedelic become a blockbuster?Compass and Usona are vying for an FDA first, but pricing, payer coverage and patient access could determine the commercial winner.BioPharma Dive · 34m ago↗ source
- More lawmakers stake out stances on China biotech investmentAhead of a Democrat-led Congress next year, more lawmakers in both parties and chambers are taking fresh positions on whether the US should restrict investments in China’s booming biotech sector. A…Endpoints · 35m ago↗ source
- US panel warns China’s biotech plan could dominate sector and threaten drug supply chainA congressional commission has warned that China’s new five-year biotech plan could allow it to dominate the global drug market. The commission says the strategy could leave U.S. patients vulnerab…